Immunology Investor Event

sanofi Dupixent: Chronic Rhinosinusitis Sans Nasal Polyposis Number of patients (thousands) Diagnosed CRSSNP Patients(1) Diagnosed type 2 CRSSNP Patients Most in need 130 Source: Sanofi analysis (1) 12+ population 10 Immunology Investor Event 2,500 4,543 0 500 1,000 1,500 2,000 2,500 3,000 3,500 4,000 4,500 5,000 US

View entire presentation